all

Although an interventional cardiologist from the beginning of coronary intervention, I have been passionate about clinical lipidology since the mid 1990's and became a Diplomate of the American Board of Clinical Lipidology in 2006. The NLA/PLA has enhanced my practice and changed my focus to prevention and treating patients with lipid disorders. I owe much to the PLA/NLA and will continue to give back to this great organization by service, participation, and contributing to its growth and influence. I encourage everyone to explore this unique and fascinating opportunity.

I am honored and excited to be the president of the SWLA for the next 12 months. I look forward to working with our board of directors and as many of the members in our region as possible. I submit that many of you have great ideas in how to grow our membership and move our organization forward - please share those ideas with us. In the end, we have a common goal - to enhance the practice of lipid management in clinical medicine. Thank you for allowing me the opportunity to lead.

Sincerely,
Kari Uusinarkaus, MD, FNLA

The 2015 Impact Factors were recently released and the Journal of Clinical Lipidology (JCL) saw yet another significant increase — from 3.904 (2014) to 4.906 (2015). The Journal is now ranked 23rd out of 253 journals in its category (pharmacology and pharmacy). The Thomson-Reuters Impact Factor represents the ratio of articles quoted in other scientific publications